The $24 billion New York firm, which bets on mergers, also pared down its stake in Allergan Inc.AGN +1.24% to 5,377,200 shares, valued at $958.2 million as of Sept. 30, and increased its position in Valeant Pharmaceuticals International Inc.'sVRX.T +0.88% to $68.3 million, according to the filing.
Smart. AGN has had a nice run but now there is more upside potential with VRX. ValueAct has been increasing it's VRX stake as well.
If he owned VXR, it was a small position. Paulson was big in Allergan and Salix which is why he was mentioned here. The buyouts made him a lot of money. He's also in Mylan, Actavis and AbbVie. Maybe these are future take over targets.